VNDA250117C3000
- 0.00
- 0.000.00%
Vanda Pharmaceuticals Newsroom
Is It a Good Idea to Invest in Vanda Pharmaceuticals Stock Now?
3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying
Express News | HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target
Vanda Pharma Analyst Ratings
Vanda Pharmaceuticals: Promising Pipeline Developments and Market Potential Drive Buy Rating
Vanda Pharmaceuticals Gets FDA Orphan-Drug Designation for Cancer Treatment
Vanda Pharmaceuticals Treatment of Polycythemia Vera Granted Orphan Status
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $18
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $13
Vanda Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Express News | Vanda Pharmaceuticals Inc : Jefferies Cuts Target Price to $5.5 From $6
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth
Vanda Pharmaceuticals Inc. (VNDA) Q3 2024 Earnings Call Transcript Summary
Vanda Pharmaceuticals | 8-K: Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
Vanda Pharmaceuticals GAAP EPS of -$0.09 Beats by $0.07, Revenue of $47.7M Misses by $1.45M
Express News | Vanda Pharmaceuticals Inc FY2024 Rev View $198.3 Mln -- LSEG IBES Data
Express News | Vanda Pharmaceuticals Inc -Financial Guidance Revised for Full Year 2024, Raising the Midpoint of Revenue and Cash Ranges
Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M